MedTrace Logo

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

NCT03859700 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 304

Last updated 2025-06-06

No results posted yet for this study

Summary

Open-label, follow-up study for subjects who completed the EPITOPE study.

Conditions

Interventions

BIOLOGICAL

DBV712 250 mcg

DBV712 250 mcg, once daily

Sponsors & Collaborators

  • DBV Technologies

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-06
Primary Completion
2025-05-13
Completion
2025-05-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03859700 on ClinicalTrials.gov